Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas Combining DC Bead Microspheres Loaded With Idarubicin (Zavedos): Phase I Trial.

Next Previous
Trial Profile

Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas Combining DC Bead Microspheres Loaded With Idarubicin (Zavedos): Phase I Trial.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idarubicin (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Acronyms IDASPHERE

Most Recent Events

  • 21 Jul 2011 Planned End Date changed from 1 Sep 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
  • 21 Jul 2011 Planned End Date changed from 1 Sep 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
  • 08 Jan 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top